Physician profile
John P White
NPI 1336148923
$1,561.68
in general payments reported to CMS, 2019-2025
30 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $57.23 · 2021: $272 · 2022: $203 · 2023: $137 · 2024: $414 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $145.51 | 2024 | Briviact |
| Sumitomo Pharma America, INC. | $129.45 | 2023-2024 | Gemtesa |
| Novo Nordisk INC | $107.66 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $106.75 | 2022 | |
| Pfizer INC. | $102.00 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $100.25 | 2021-2022 | |
| Lilly USA, LLC | $99.41 | 2019-2025 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $85.91 | 2020-2021 | |
| Abbvie INC. | $81.01 | 2021 | |
| Glaxosmithkline, LLC. | $60.96 | 2019 | |
| Nestle Healthcare Nutrition INC. | $52.60 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.84 | 2024-2025 | Caplyta |
| Amgen INC. | $46.65 | 2024-2025 | Repatha, Otezla, Repatha |
| Eisai INC. | $45.91 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $43.56 | 2019-2025 | Farxiga |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.24 | 2019 | |
| Exact Sciences Corporation | $37.88 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $33.77 | 2020-2024 | Rexulti |
| Genentech USA, INC. | $26.10 | 2019 | |
| Lundbeck LLC | $21.46 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $18.61 | 2021 | |
| Neurelis, INC. | $16.19 | 2023 | Valtoco |
| Amarin Pharma, INC. | $15.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.25 | 2019 | |
| Kyowa Kirin, INC. | $14.49 | 2023 | Crysvita |
| Neurocrine Biosciences, INC. | $13.74 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $13.01 | 2023 | Evkeeza |
| Janssen Pharmaceuticals, INC | $12.48 | 2019 | |
| Sanofi Pasteur INC. | $12.36 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.